- Home
- ZVSA vs JTAI Comparison
ZVSA vs JTAI Comparison
Compare ZVSA & JTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- JTAI
- Stock Information
- Founded
- ZVSA 2014
- JTAI 2018
- Country
- ZVSA United States
- JTAI United States
- Employees
- ZVSA N/A
- JTAI N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- JTAI Blank Checks
- Sector
- ZVSA Health Care
- JTAI Finance
- Exchange
- ZVSA Nasdaq
- JTAI Nasdaq
- Market Cap
- ZVSA 2.3M
- JTAI 2.7M
- IPO Year
- ZVSA N/A
- JTAI N/A
- Fundamental
- Price
- ZVSA $1.08
- JTAI $5.35
- Analyst Decision
- ZVSA Strong Buy
- JTAI
- Analyst Count
- ZVSA 1
- JTAI 0
- Target Price
- ZVSA $240.00
- JTAI N/A
- AVG Volume (30 Days)
- ZVSA 3.6M
- JTAI 246.5K
- Earning Date
- ZVSA 11-14-2024
- JTAI 11-14-2024
- Dividend Yield
- ZVSA N/A
- JTAI N/A
- EPS Growth
- ZVSA N/A
- JTAI N/A
- EPS
- ZVSA N/A
- JTAI N/A
- Revenue
- ZVSA N/A
- JTAI $15,028,926.00
- Revenue This Year
- ZVSA N/A
- JTAI $42.02
- Revenue Next Year
- ZVSA N/A
- JTAI N/A
- P/E Ratio
- ZVSA N/A
- JTAI N/A
- Revenue Growth
- ZVSA N/A
- JTAI 46.66
- 52 Week Low
- ZVSA $1.05
- JTAI $5.17
- 52 Week High
- ZVSA $42.35
- JTAI $1,005.75
- Technical
- Relative Strength Index (RSI)
- ZVSA 27.91
- JTAI 26.28
- Support Level
- ZVSA $1.34
- JTAI $5.90
- Resistance Level
- ZVSA $1.89
- JTAI $10.36
- Average True Range (ATR)
- ZVSA 0.25
- JTAI 2.17
- MACD
- ZVSA -0.08
- JTAI -0.52
- Stochastic Oscillator
- ZVSA 1.29
- JTAI 1.58
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as via Jet Token's leased and managed aircraft.